ICML 2019 | IR plus R-HCVAD/R-MTX efficacious for young MCL in the first-line

Preetesh Jain

A study of ibrutinib-rituximab plus short course R-HCVAD/R-MTX for previously untreated, young mantle cell lymphoma (MCL) patients was presented by M. Wang at the 15th International Conference on Malignant Lymphoma (ICML), in Lugano, Switzerland. Here, his colleague Preetesh Jain, MD, PhD, MD Anderson Cancer Center, Houston, Texas, TX, discusses the findings.

Share this video